Sanid. mil. 2021; 77 (1) 3
Sanidad Militar
Revista de Sanidad de las Fuerzas Armadas de España
Sanid. Mil. Volumen 77, número 1. ISSN: 1887-8571 Enero-marzo 2021
CONTENTS
EDITORIAL
5 125th anniversary of the Central Defense Hospital «Gómez Ulla»
Fernández-Tapia-Ruano M.
ORIGINAL ARTICLE
7 Dynamic model of COVID19 pandemic
Delgado J.A.
SUMMARY: The COVID19 pandemic is generating an international effort to know the main dynamic aspects that this new
epidemic crisis is causing, which is why a large number of initiatives are emerging around the world in relation to the development
of mathematical models. The present work develops a dynamic simulation model based on the Systems Dynamics
technique, under a systemic vision approach of the social and health problems it raises. The results have been simulated with
respect to the casuistry of the Community of Madrid. The tremendous problem posed by the group of undetected infected,
the cause of the spread of the epidemic, as well as the evidence of the technical difficulty posed by the lack of reliability of
official data, for this reason, is evident.
KEY WORDS: COVID19, Pandemic, Models, Systems Dynamic.
17 The injury pattern and its relation to the severity score in the combat casualty
García-Cañas R., Navarro-Suay R., Rodríguez-Moro C., Crego-Vita D.M, Bernácer-López J.L., Areta-Jiménez F.J.
SUMMARY: Introduction: Knowing the distribution and type of injury in the combatant is a useful tool in the medical
support planning for military operations.The objective of this work is to analyze the anatomical distribution of war wounds
and determine the relationship with severity according to military Injury Severity Score (mISS) applied to combat casualties.
Material and methods: A retrospective, descriptive and cross-sectional study was carried out on all patients injured by firearms
or explosives treated in the Spanish Role 2 of Herat between 2005 and 2014. Results: A total of 911 combat casualties with
1689 war injuries were analyzed. The body region most affected were the lower limbs (30.19%), followed by the upper limbs
(22.49%) and the craniofacial region (19.06%). Statistically significant differences were found in the distribution of the mISS
scores according to the number of anatomical areas affected and between casualties that suffered injuries to the trunk and
abdomen and those that did not. Conclusions: The injury pattern in combat casualties treated in the Spanish Role 2 of Herat
was characterized by injury to the extremities, mainly affecting the lower limbs. Those casualties with injuries to the trunk
and abdomen were those with significantly higher scores on the mISS. The severity of the casualties was directly related to the
number of anatomical areas affected.
KEYWORDS: Combat casualty, injury pattern, injury severity score, Role 2, Spanish Medical Corps, Afghanistan.
SHORT COMMUNICATION
26 The treatment of Elephantiasis nostras verrucosa with TCA
Armengol-de-la-Hoz J.M., Martínez-Murillo A., Espejo-Ortega L.F.
SUMMARY: Elephantiasis nostras verrucosa is a rare dermatological condition characterized by edema, foul-smelling hyperkeratosis
with generalized lichenification, cobblestone papules, and warty changes. The pathology is produced by congenital
or secondary chronic obstructive lymphedema. There is no clear consensus for the treatment of this pathology. In this article
we present a clinical case of a 73 years old woman who was treated with 25% trichloracetic acid with satisfactory results.
KEY WORDS: Lymphedema, Elephantiasis nostras verrucosa, trichloracetic acid, myiasis.
TECHNICAL NOTES
29 Positive assessment of drugs: October 2020
Aparicio-Hernández R., García-Luque A., Acuña-Vega A., Granda-Lobato P.
SUMMARY: The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency
made public in October of 2019, and considered of interest to the healthcare professional, are reviewed. These are positive
technical reports prior to the authorization and placing on the market of the product.
KEYWORDS: Cabotegravir (Vocabria®); Células CD3+ autólogas transducidas anti CD-19 (Tecartus®); Cultivo celular
autólogo de CD34+, enriquecido con células madre y células progenitoras hematopoyéticas transducidas ex vivo usando un
vector lentiviral (lentivirus) con el gen humano arilsulfatasa A (Libmeldy®); Fenfluramina (Fintepla®); Formoterol 5 μ/9 μG
Bromuro de glicopirronio/160 μG Budesonida (Trixeo Aerosphere®); Inclisirán (Leqvio®); Lumasiran (Oxlumo®); Polvo
desengrasado de arachis hypogaea l. (semilla de cacahuete) (Palforzia®); Rilpivirina (Rekambys®).